Treatment of severely open tibial fractures, non-unions, and fracture-related infections with a gentamicin-coated tibial nail-clinical outcomes including quality of life analysis and psychological ICD-10-based symptom rating.


Journal

Journal of orthopaedic surgery and research
ISSN: 1749-799X
Titre abrégé: J Orthop Surg Res
Pays: England
ID NLM: 101265112

Informations de publication

Date de publication:
17 Apr 2021
Historique:
received: 06 01 2021
accepted: 06 04 2021
entrez: 18 4 2021
pubmed: 19 4 2021
medline: 6 10 2021
Statut: epublish

Résumé

Implant-associated infections depict a major challenge in orthopedics and trauma surgery putting a high burden on the patients and health care systems, strongly requiring improvement of infection prevention and of clinical outcomes. One strategy includes the usage of antimicrobial-coated implants. We evaluated outcomes after surgical treatment using a gentamicin-coated nail on (i) treatment success in terms of bone consolidation, (ii) absence of infection, and (iii) patient-reported quality of life in a patient cohort with high risk of infection/reinfection and treatment failure. Thirteen patients with open tibia fractures (n = 4), non-unions (n = 2), and fracture-related infection (n = 7) treated with a gentamicin-coated intramedullary nail (ETN Protect At a mean follow-up of 2.8 years, 11 of the 13 patients (84.6%) achieved bone consolidation without any additional surgical intervention, whereas two patients required a revision surgery due to infection and removal of the implant. No specific implant-related side effects were noted. Quality of life scores were significantly lower compared to a German age-matched reference population. The mean ISR scores revealed mild psychological symptom burden on the scale depression. The use of a gentamicin-coated intramedullary nail seems to be reasonable in open fractures and revision surgery for aseptic non-union or established fracture-related infection to avoid infection complications and to achieve bony union. Despite successful treatment of challenging cases with the gentamicin-treated implant, significantly reduced quality of life after treatment underlines the need of further efforts to improve surgical treatment strategies and psychological support.

Sections du résumé

BACKGROUND BACKGROUND
Implant-associated infections depict a major challenge in orthopedics and trauma surgery putting a high burden on the patients and health care systems, strongly requiring improvement of infection prevention and of clinical outcomes. One strategy includes the usage of antimicrobial-coated implants. We evaluated outcomes after surgical treatment using a gentamicin-coated nail on (i) treatment success in terms of bone consolidation, (ii) absence of infection, and (iii) patient-reported quality of life in a patient cohort with high risk of infection/reinfection and treatment failure.
METHODS METHODS
Thirteen patients with open tibia fractures (n = 4), non-unions (n = 2), and fracture-related infection (n = 7) treated with a gentamicin-coated intramedullary nail (ETN Protect
RESULTS RESULTS
At a mean follow-up of 2.8 years, 11 of the 13 patients (84.6%) achieved bone consolidation without any additional surgical intervention, whereas two patients required a revision surgery due to infection and removal of the implant. No specific implant-related side effects were noted. Quality of life scores were significantly lower compared to a German age-matched reference population. The mean ISR scores revealed mild psychological symptom burden on the scale depression.
CONCLUSION CONCLUSIONS
The use of a gentamicin-coated intramedullary nail seems to be reasonable in open fractures and revision surgery for aseptic non-union or established fracture-related infection to avoid infection complications and to achieve bony union. Despite successful treatment of challenging cases with the gentamicin-treated implant, significantly reduced quality of life after treatment underlines the need of further efforts to improve surgical treatment strategies and psychological support.

Identifiants

pubmed: 33865407
doi: 10.1186/s13018-021-02411-8
pii: 10.1186/s13018-021-02411-8
pmc: PMC8052745
doi:

Substances chimiques

Anti-Bacterial Agents 0
Gentamicins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

270

Références

Chirurg. 1970 Nov;41(11):511-5
pubmed: 5487941
Injury. 2020 May;51 Suppl 2:S57-S63
pubmed: 31679836
Bone Joint J. 2015 Jun;97-B(6):814-7
pubmed: 26033062
Chin J Traumatol. 2019 Oct;22(5):270-273
pubmed: 31443939
Acta Orthop. 2011 Feb;82(1):82-9
pubmed: 21189112
Health Policy. 1996 Jul;37(1):53-72
pubmed: 10158943
Ther Clin Risk Manag. 2016 Sep 07;12:1387-93
pubmed: 27660456
Injury. 2020 Aug;51 Suppl 3:S86-S91
pubmed: 31591005
Arch Orthop Trauma Surg. 2019 Jan;139(1):61-72
pubmed: 30343322
Z Psychosom Med Psychother. 2008;54(4):409-18
pubmed: 19049690
Injury. 2018 Dec;49(12):2161-2166
pubmed: 30526922
Arch Orthop Trauma Surg. 2011 Oct;131(10):1419-25
pubmed: 21617934
J Orthop Res. 2018 Mar;36(3):945-953
pubmed: 28833572
Injury. 2017 Oct;48(10):2235-2241
pubmed: 28734495
Injury. 2006 May;37 Suppl 2:S59-66
pubmed: 16651073
Bone Joint Res. 2019 Jun 5;8(5):199-206
pubmed: 31214332
Injury. 2015 Dec;46(12):2433-7
pubmed: 26477343
J Bone Joint Surg Am. 1976 Jun;58(4):453-8
pubmed: 773941
Int Orthop. 2019 Feb;43(2):261-267
pubmed: 29946740
J Bone Joint Surg Am. 2017 Mar 1;99(5):388-395
pubmed: 28244909
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2004 Nov;47(11):1027-32
pubmed: 15549195
Injury. 2012 Jul;43(7):1071-8
pubmed: 22356720
Injury. 2018 Mar;49(3):511-522
pubmed: 27639601
Int Orthop. 2017 Dec;41(12):2457-2469
pubmed: 28831576
Appl Health Econ Health Policy. 2017 Apr;15(2):127-137
pubmed: 28194657
J Bone Joint Surg Am. 2013 Dec 18;95(24):2170-6
pubmed: 24352770
Injury. 2007 May;38 Suppl 2:S19-22
pubmed: 17920413
Health Policy. 1990 Dec;16(3):199-208
pubmed: 10109801
Injury. 2017 Mar;48(3):599-607
pubmed: 28088378
J Biol Regul Homeost Agents. 2020 May-Jun;34(3 Suppl. 2):63-69
pubmed: 32856442
J Clin Med. 2019 Nov 15;8(11):
pubmed: 31731803
Eur J Trauma Emerg Surg. 2021 Feb;47(1):121-127
pubmed: 31134291
Injury. 2014 Jul;45(7):1025-7
pubmed: 24794617
Injury. 2018 Mar;49(3):505-510
pubmed: 28867644

Auteurs

Nike Walter (N)

Department for Trauma Surgery, University Medical Center Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany.
Department for Psychosomatic Medicine, University Medical Center Regensburg, Regensburg, Germany.

Daniel Popp (D)

Department for Trauma Surgery, University Medical Center Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany.

Viola Freigang (V)

Department for Trauma Surgery, University Medical Center Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany.

Michael Nerlich (M)

Department for Trauma Surgery, University Medical Center Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany.

Volker Alt (V)

Department for Trauma Surgery, University Medical Center Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany.

Markus Rupp (M)

Department for Trauma Surgery, University Medical Center Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany. markus.rupp@ukr.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH